Informational Alert

Our new building on the hospital campus, Forest B, is open. Families and visitors can park in the new Forest B garage next to Emergency.

Center for Global Infectious Disease Research
Back to... ➝
Donate Now
Coler Lab Menu
Back to... ➝
Donate Now

Publications

Mycobacteria

Baldwin SL, Reese VA, Larsen SE, Pecor T, Brown BP, Granger B, Podell BK, Fox CB, Reed SG and Coler RN (2022) Therapeutic efficacy against Mycobacterium tuberculosis using ID93 and liposomal adjuvant formulations. Front. Microbiol. 13:935444. doi: 10.3389/fmicb.2022.935444

Abdelaal HFM, Chan ED, Young L, Baldwin SL, and Coler RN, 'Mycobacterium abcessus: It's Complex', Microorganisms, 2022, 10, 1454.

Baldwin SL, Reese VA, Larsen SE, Beebe E, Guderian J, Orr MT, Fox CB, Reed SG, Coler RN. Prophylactic efficacy against Mycobacterium tuberculosis using ID93 and lipid-based adjuvant formulations in the mouse model. Plos one. 2021 Mar 11;16(3):e0247990.

Day T, Penn-Nicholson A, Luabeya A, Fiore-Gartland A, Du Plessis N, Loxton AG, Vergara J, Rolf T, Reid T, Toefy A, Shenje J, Geldenhuys H, Tameris M, Mabwe S, Bilek N, Bekker LG, Diacon A, Walzl G, Ashman J, Frevol A, Sagawa ZK, Reed SG, Scriba T, Hatherill M, Coler RN. Safety and immunogenicity of the adjunct therapeutic vaccine ID93 + GLA-SE in treated tuberculosis patients: a randomized double-blind placebo-controlled trial. Lancet Respiratory Medicine. Online 2020. DOI: https://doi.org/10.1016/S2213-2600(20)30319-2.

Carrigy NB, Larsen SE, Reese V, Pecor T, Harrison M, Kuehl PJ, Hatfull GF, Sauvageau D, Baldwin SL, Finlay WH, Coler RN, Vehring R. Prophylaxis of Mycobacterium tuberculosis H37Rv Infection in a Preclinical Mouse Model via Inhalation of Nebulized Bacteriophage D29. Antimicrob Agents Chemother. 2019 Sep 16;. doi: 10.1128/AAC.00871-19. [Epub ahead of print] PubMed PMID: 31527037; PubMed Central PMCID: PMC6879268.

Larsen SE, Reese VA, Pecor T, Berube BJ, Cooper SK, Brewer G, Ordway D, Henao-Tamayo M, Podell BK, Baldwin SL, Coler RN. Subunit vaccine protects against a clinical isolate of Mycobacterium avium in wild type and immunocompromised mouse models. Scientific reports. 2021 Apr 27;11(1):1-6.

Baldwin SL, Larsen SE, Ordway D, Cassell G, Coler RN. The complexities and challenges of preventing and treating nontuberculous mycobacterial diseases. PLoS Negl Trop Dis. 2019;13(2):e0007083. PMID: 30763316. PMC6375572.

Coler RN, Day TA, Ellis R, Piazza FM, Beckmann AM, Vergara J, Rolf T, Lu L, Alter G, Hokey D, Jayashankar L, Walker R, Snowden MA, Evans T, Ginsberg A, Reed SG, Team T-S. The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial. NPJ Vaccines. 2018;3:34. PMID: 30210819.PMC6123489.

SARS-CoV-2

Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al. An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. N Engl J Med. 2020. Epub 2020/07/15. doi: 10.1056/NEJMoa2022483. PubMed PMID: 32663912; PMCID: PMC7377258.

Larsen SE, Berube BJ, Pecor T, Cross E, Brown BP, Williams B, Johnson E, Qu P, Carter L, Wrenn S, Kepl E, Sydeman C, King NP, Baldwin SL, Coler RN. Qualification of ELISA and neutralization methodologies to measure SARS-CoV-2 humoral immunity using human clinical samples. bioRxiv. 2021 Jul 2;. doi: 10.1101/2021.07.02.450915. PubMed PMID: 34230930; PubMed Central PMCID: PMC8259906.

Other

Van Hoeven N, Wiley S, Gage E, Fiore-Gartland A, Granger B, Gray S, Fox C, Clements DE, Parks DE, Winram S, Stinchcomb DT, Reed SG, Coler RN. A combination of TLR-4 agonist and saponin adjuvants increases antibody diversity and protective efficacy of a recombinant West Nile Virus antigen. NPJ Vaccines. 2018;3:39. doi: 10.1038/s41541-018-0077-1. PubMed PMID: 30302281.PMC6158298.

Baldwin SL, Hsu FC, Van Hoeven N, Gage E, Granger B, Guderian JA, Larsen SE, Lorenzo EC, Haynes L, Reed SG, Coler RN. Improved Immune Responses in Young and Aged Mice with Adjuvanted Vaccines against H1N1 Influenza Infection. Front Immunol. 2018 Feb 19;9:295. PMID: 29515589; PMCID: PMC5826078.

Seattle Children’s complies with applicable federal and other civil rights laws and does not discriminate, exclude people or treat them differently based on race, color, religion (creed), sex, gender identity or expression, sexual orientation, national origin (ancestry), age, disability, or any other status protected by applicable federal, state or local law. Financial assistance for medically necessary services is based on family income and hospital resources and is provided to children under age 21 whose primary residence is in Washington, Alaska, Montana or Idaho.